Creative Biolabs is one of the leading custom antibody generation and development providers. We specialize in the generation of antibodies against a wide range of targets for R&D, diagnostic, and therapeutic applications. Currently, we have launched a series of in vitro diagnostic (IVD) antibody development services targeting numerous diagnostic biomarkers of human diseases. Here, we focus on the IGHD as a marker of lymph cancer.
Immunoglobulin Heavy Constant Delta (IGHD)
Ig delta chain C region is a protein that is encoded by the IGHD gene in humans. Other names include Ig delta chain C region; immunoglobulin delta; constant region of heavy chain of IgD. The encoded protein has an amino acid length of 384 and a mass of 42.3 kDa. This gene shares homology with other species, including Zebrafish.
IGHD Marker of Lymph Cancer
Chronic lymphocytic leukemia (CLL) results from the clonal expansion of mature B lymphocytes and is characterized by extreme clinical heterogeneity. One of the most reliable prognostic markers in chronic lymphocytic leukemia (CLL) is the mutational status of immunoglobulin heavy variable (IGHV) genes, which defines 2 subsets, mutated CLL (M-CLL) and unmutated CLL (U-CLL), with different clinical courses. Biased IGHV gene used between M-CLL and U-CLL clones, as well as population differences in the IGHV gene repertoire, have been reported.
Fig 1. Anatomy of the lymph system, showing the lymph vessels and lymph organs including lymph nodes, tonsils, thymus, spleen, and bone marrow.
The mutational status and configuration of IGHV gene rearrangements were analyzed in 85 Serbian patients with chronic lymphocytic leukemia. It is found that 55.3% of cases belonged to mutated and 44.7% to unmutated CLL, progressive disease predominating in the unmutated subset. Besides, survival of patients with B cell chronic lymphocytic leukemia can be predicted by analysis of mutations in the IGHV. Patients without mutations (unmutated [UM]) are at greater risk for disease progression and death than patients with mutations. Despite this broad prognostic difference, there remains wide intragroup variation in the clinical outcome of UM patients, especially those with low/intermediate Rai risk disease.
IVD antibodies are extensively used in immunodiagnostic tools for disease screening and therapeutic monitoring. Through our role as a leading antibody service provider, Creative Biolabs is well-positioned to develop high-quality IGHD-specific antibodies. Besides antibody generation, Creative Biolabs also offers diagnostic immunoassay development services, including feasibility analysis, assay design, assay protocol establishment, assay optimization, and kit production.
Creative Biolabs has successfully completed a number of IVD antibody generation and development projects for clients across the globe. If you are interested in our services, please contact us to discuss your project needs.
For Research Use Only.
